Journal article
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of Tau pathology in Alzheimer disease
N Okamura, S Furumoto, R Harada, T Tago, T Yoshikawa, M Fodero-Tavoletti, RS Mulligan, VL Villemagne, H Akatsu, T Yamamoto, H Arai, R Iwata, K Yanai, Y Kudo
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2013
Abstract
Neurofibrillary tangles in Alzheimer disease (AD) brains are composed of the microtubule-associated protein tau. Noninvasive monitoring of tau protein aggregates in the living brain will provide useful information regarding tau pathophysiology in AD. However, no PET probes are currently available for selective detection of tau pathology in AD. We have previously reported 18F-labeled THK-523 (18F-6-(2-fluoroethoxy)-2-(4- aminophenyl)quinoline) as a tau imaging radiotracer candidate for PET. After compound optimization, we developed novel 18F-labeled arylquinoline derivatives, 18F-THK- 5105 and 18F-THK-5117, for use as tau imaging PET tracers. Methods: 18F-labeled compounds were prepared from ..
View full abstractGrants
Awarded by Japan Society for the Promotion of Science
Funding Acknowledgements
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This study was supported by the research fund from GE Healthcare; the Industrial Technology Research Grant Program of the NEDO in Japan (09E51025a); Health and Labor Sciences Research grants from the Ministry of Health, Labor, and Welfare of Japan; and a Grant-in-Aid for Scientific Research (B) (23390297) and "Japan Advanced Molecular Imaging Program (J-AMP)" of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. No other potential conflict of interest relevant to this article was reported.